(Q41050632)

26 September 2017

title

Dopamine receptor alteration in schizophrenia: neuroendocrine evidence (English)

1 reference

26 September 2017

1 reference

J Rotrosen

1

1 reference

26 September 2017

B M Angrist

2

1 reference

26 September 2017

S Gershon

3

1 reference

26 September 2017

E J Sachar

4

1 reference

26 September 2017

F S Halpern

5

1 reference

26 September 2017

publication date

1 December 1976

1 reference

26 September 2017

1 reference

26 September 2017

volume

51

1 reference

26 September 2017

issue

1

1 reference

26 September 2017

page(s)

1-7

1 reference

Evidence for dopamine receptor stimulation by apomorphine.

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF00426313

The basis for amine hypotheses in affective disorders. A critical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00426313

Central dopamine turnover in schizophrenic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00426313

Diagnostic Criteria for Use in Psychiatric Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00426313

Effect of Five Dopaminergic Drugs on Plasma Growth Hormone Levels in Acromegalic Subjects

21 January 2018

1 reference

12 December 2020

Apomorphine: Effect on Growth Hormone

1 reference

12 December 2020

Excitation-mediating and inhibition-mediating dopamine-receptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data

1 reference

12 December 2020

Increased Plasma Levels of Growth Hormone During Infusion of Propranolol

1 reference

12 December 2020

Suppression of Human Growth Hormone Secretion by Melatonin and Cyproheptadine

1 reference

12 December 2020

Effects of apomorphine and amphetamine on schedule-controlled behavior: Reversal of tetrabenazine suppression and dopaminergic correlates

1 reference

12 December 2020

Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?

1 reference

12 December 2020

Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men

1 reference

12 December 2020

Stable Reduction of Plasma Growth Hormone (hGH) Levels During Chronic Administration of 2-Br-α-ergocryptine (CB-154) in Acromegalic Patients

1 reference

12 December 2020

5-Hydroxyindoleacetic acid (5 HIAA) and homovanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines

1 reference

12 December 2020

Effect of 5-hydroxytryptophan (5-HTP) on growth hormone and ACTH release in man

1 reference

12 December 2020

Effect of psychotropic drugs on tryptophan concentration in the rat brain

1 reference

12 December 2020

Drugs, neurotransmitters, and schizophrenia

1 reference

12 December 2020

Circadian Variation of Integrated Concentration of Growth Hormone in Children and Adults

1 reference

12 December 2020

Growth hormone catecholamines in affective disease

1 reference

12 December 2020

Protein Intake and Treatment of Parkinson's Disease with Levodopa

1 reference

12 December 2020

Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats

1 reference

12 December 2020

Pattern of Plasma ACTH, hGH, and Cortisol During Menstrual Cycle

1 reference

12 December 2020

Suppression of sleep-related prolactin secretion and enhancement of sleep-related growth hormone secretion

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00426313

1 reference

Dimensions Publication ID

26 September 2017

1000647919

0 references

1 reference